STAT in a recent report takes a look at the track record of Phlow CEO Eric Edwards, who the Trump administration tapped to manufacture generic drugs in short supply.
According to the report, Kaleo, which was founded by Edwards and his brother, hiked the price of its opioid overdose drug, Evzio, by more than 600 percent between 2014-2017.
“Maybe this company is the best one for the job, but it does raise eyebrows,” Holly Lynch, assistant professor of medical ethics at the University of Pennsylvania, told STAT. “One would hope that CEOs who behave in a way that is not in the public interest are not rewarded by the federal government a couple of years later.”
To read the full report, click here.